SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：0
|
作者：
Nash, P. [1 ]
Coates, L. C. [2 ]
Kivitz, A. J. [3 ]
Mease, P. J. [4 ,5 ]
Gladman, D. D. [6 ]
Covarrubias-Cobos, J. A. [7 ]
Fleishaker, D. [8 ]
Wang, C. [8 ]
Kudlacz, E. [8 ]
Menon, S. [8 ]
Fallon, L. [9 ]
Hendrikx, T. [10 ]
Kanik, K. S. [8 ]
机构：
[1] Univ Queensland, Brisbane, Qld, Australia
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Altoona Ctr Clin Res, Duncansville, PA USA
[4] Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Univ Toronto, Toronto, ON, Canada
[7] Unidad Reumatol Las Americas SCP, Merida, Mexico
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Canada, Montreal, PQ, Canada
[10] Pfizer Inc, Collegeville, PA USA
来源：
INTERNAL MEDICINE JOURNAL | 2018年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P11
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [11] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [12] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [13] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Riese, R.
    Wang, L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
  • [14] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, P.
    Genovese, M. C.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 66
  • [15] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, Peter
    Genovese, Mark
    Keystone, Ed
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A31 - A31
  • [16] Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study
    Taylor, P.
    Genovese, M.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    Lundmark, J.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 59 - 59
  • [17] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Chan, Gary
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S328 - S328
  • [18] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Studies up to 36 Months.
    Wollenhaupt, J.
    Silverfield, J. C.
    Lee, E. B.
    Wood, S.
    Soma, K.
    Wang, L.
    Nakamura, H.
    Komuro, Y.
    Nduaka, C. I.
    Gruben, D.
    Zwillich, S. H.
    Bradley, J. D.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S152 - S153
  • [19] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Soonasra, Arif
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414
  • [20] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 8 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K.
    Kwok, K.
    Abramsky, S.
    Wang, M.
    Nduaka, C.
    DeMasi, R.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 277 - 278
12345